SWSvenja Wagener-Ryczek

Svenja Wagener-Ryczek

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Svenja Wagener-Ryczek has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Reinhard Buettner

    Institute for Pathology and Center for Integrated Oncology (CIO), University Hospital Cologne, Cologne, Germany

    2 shared publications
  • Sabine Merkelbach-Bruse

    Institute of Pathology, University Hospital of Cologne, Cologne, Germany

    2 shared publications
  • Alexander Quaas

    Institute of Pathology, University Hospital Cologne, Cologne, Germany

    1 shared publication
  • Carina Heydt

    Institute of Pathology, University Hospital of Cologne, Cologne, Germany

    1 shared publication
  • Christiane Bruns

    Department of General, Visceral, Cancer and Transplantation Surgery, University Hospital Cologne, Cologne, Germany

    1 shared publication
  • Christina Alidousty

    Institute of Pathology, University Hospital of Cologne, Cologne, Germany

    1 shared publication

Latest Publications

  • Open Access

    Biomarkers for Homologous Recombination Deficiency in Cancer

    by Svenja Wagener-Ryczek, Sabine Merkelbach-Bruse, Janna Siemanowski

    DNA double-strand breaks foster tumorigenesis and cell death. Two distinct mechanisms can be activated by the cell for DNA repair: the accurate mechanism of homologous recombination repair or the error-prone non-homologous end joining. Homologous Recombination Deficiency (HRD) is associated with sensitivity towards PARP inhibitors (PARPi) and its determination is used as a biomarker for therapy decision making. Nevertheless, the biology of HRD is rather complex and the application, as well as the benefit of the different HRD biomarker assays, is controversial. Acquiring knowledge of the underlying molecular mechanisms is the main prerequisite for integration of new biomarker tests. This study presents an overview of the major DNA repair mechanisms and defines the concepts of HRR, HRD and BRCAness. Moreover, currently available biomarker assays are described and discussed with respect to their application for routine clinical diagnostics. Since patient stratification for efficient PARP inhibitor therapy requires determination of the BRCA mutation status and genomic instability, both should be established comprehensively. For this purpose, a broad spectrum of distinct assays to determine such combined HRD scores is already available. Nevertheless, all tests require careful validation using clinical samples to meet the criteria for their establishment in clinical testing.


  • Targeted RNA-sequencing for the evaluation of gene fusions in lung tumors: current status and future prospects

    by Svenja Wagener-Ryczek, Roberto Pappesch

    Routinely, patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) are screened for mutations and fusions to direct therapy decision. The majority of molecular laboratories ...


  • The value of tumor mutational burden to select patients for immunotherapy

    by Svenja Wagener-Ryczek, Reinhard Buettner

    One of the most promising and currently available immune therapies is PD-1/PD-L1 inhibition. However, response rates in unselected patient cohorts still remain unsatisfactory, limiting the applicat...


  • Open Access

    Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors

    by Svenja Wagener-Ryczek, Carina Heydt, Juliane Süptitz, Sebastian Michels, Markus Falk, Christina Alidousty, Jana Fassunke, Michaela Angelika Ihle, Markus Tiemann, Lukas Heukamp, et al.

    Background: Over the past years, EGFR tyrosine kinase inhibitors (TKI) revolutionized treatment response. 1st-generation (reversible) EGFR TKI and later the 2nd –generation irreversible EGFR TKI Afatinib were aimed to improve treatment response. Nevertheless, diverse resistance mechanisms develop within the first year of therapy. Here, we evaluate the prevalence of acquired resistance mechanisms towards reversible and irreversible EGFR TKI.Methods: Rebiopsies of patients after progression to EGFR TKI therapy (> 6 months) were targeted to histological and molecular analysis. Multiplexed targeted sequencing (NGS) was conducted to identify acquired resistance mutations (e.g. EGFR p.T790M). Further, Fluorescence in situ hybridisation (FISH) was applied to investigate the status of bypass mechanisms like, MET or HER2 amplification.Results: One hundred twenty-three rebiopsy samples of patients that underwent first-line EGFR TKI therapy (PFS ≥6 months) were histologically and molecularly profiled upon clinical progression. TheEGFRp.T790M mutation is the major mechanism of acquired resistance in patients treated with reversible as well as irreversible EGFR TKI. Nevertheless a statistically significant difference for the acquisition of T790M mutation has been identified: 45% of afatinib- vs 65% of reversible EGFR TKI treated patients developed a T790M mutation (p-value 0.02). Progression free survival (PFS) was comparable in patients treated with irreversibleEGFRirrespective of the sensitising primary mutation or the acquisition of p.T790M.Conclusions: TheEGFRp.T790M mutation is the most prominent mechanism of resistance to reversible and irreversible EGFR TKI therapy. Nevertheless there is a statistically significant difference of p.T790M acquisition between the two types of TKI, which might be of importance for clinical therapy decision.


  • Open Access

    Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma

    by Svenja Wagener-Ryczek, Max Schoemmel, Max Kraemer, Christiane Bruns, Wolfgang Schroeder, Thomas Zander, Florian Gebauer, Hakan Alakus, Sabine Merkelbach-Bruse, Reinhard Buettner, et al.

    The outcome in esophageal adenocarcinoma (EAC) is still poor with only 20% of patients in Western populations surviving for more than 5 years. Almost nothing is known about the precise composition of immune cells and their gene expression profiles in primary resected EACs and also nothing compared to neoadjuvant treated EACs. This study analyzes and compares immune profiles of primary resected and neoadjuvant treated esophageal adenocarcinoma and unravels possible targets for immunotherapy. We analyzed 47 EAC in total considering a set of 30 primary treatment-naive EACs and 17 neoadjuvant pretreated (12 × CROSS, 5 × FLOT) using the Nanostring's panel-based gene expression platform including 770 genes being important in malignant tumors and their immune micromileu. Most of the significantly altered genes are involved in the regulation of immune responses, T-and B cell functions as well as antigen processing. Chemokine-receptor axes like the CXCL9, -10,-11/CXCR3- are prominent in esophageal adenocarcinoma with a fold change of up to 9.5 promoting cancer cell proliferation and metastasis. ARG1, as a regulator of T-cell fate is sixfold down-regulated in untreated primary esophageal tumors. The influence of the currently used neoadjuvant treatment revealed a down-regulation of nearly all important checkpoint markers and inflammatory related genes in the local microenvironment. We found a higher expression of checkpoint markers like LAG3, TIM3, CTLA4 and CD276 in comparison to PD-L1/PD-1 supporting clinical trials analyzing the efficacy of a combination of different checkpoint inhibitors in EACs. We found an up-regulation of CD38 or LILRB1 as examples of additional immune escape mechanism.